[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Bastiaan Driehuys\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":190},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,46,67,91,117,141,166],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100543090","phase-2-129-xenon-imaging-in-patients-treated-with-sotatercept-100543090",false,"NCT06351345","129 Xenon Imaging in Patients Treated With Sotatercept","129Xenon MR Imaging and Spectroscopy Response to Sotatercept in Pulmonary Arterial Hypertension","Sox-PH","Inclusion Criteria:\n\n1. Outpatients of either gender, Age 18-75\n2. Diagnosis of precapillary PH (right heart catheterization demonstrating hemodynamic criteria of a mean pulmonary artery pressure (mPAP) ≥ 20 mmHg, pulmonary vascular resistance ≥ 5 WU, pulmonary capillary wedge pressure ≤ 15 mmHg) in the setting of Group 1 (PAH)\n3. Willing and giving informed consent and adhere to visit\u002Fprotocol schedules (consent must be given before any study procedures are performed).\n4. On a stable dose of background PAH therapy for \\> 90 days prior to study enrollment\n5. Women of childbearing potential must have a negative urine pregnancy test before MRI\n\nExclusion Criteria:\n\n1. Moderate to severe heart disease (LVEF \\\u003C 45%, Severe LV hypertrophy, Moderate to severe valvular disease)\n2. Chronic thromboembolic disease\n3. PH due to schistosomiasis\n4. Active cancer\n5. Sickle cell anemia\n6. Prisoners and pregnant women will not be approached for the study\n7. Conditions that will prohibit MRI scanning (metal in eye, claustrophobia, inability to lie supine)\n8. Medical or psychological conditions which, in the opinion of the investigator, might create undue risk to the participant or interfere with the participant's ability to comply with the protocol requirements","ALL","18 Years","75 Years",{"count":21,"type":22},14,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","Determine the ability of 129Xe MRI\u002FMRS biomarker signatures to non-invasively monitor pulmonary vascular reverse remodeling induced by sotatercept in pulmonary arterial hypertension (PAH).",[28,29],"Pulmonary Hypertension","Pulmonary Arterial Hypertension",[31,32],"Xenon","MRI","RECRUITING","2026-02-23",{"date":36,"type":37},"2026-02-24","ACTUAL",{"date":39,"type":37},"2025-10-27",{"date":41,"type":22},"2030-02-04",{"name":43,"class":44},"Bastiaan Driehuys","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":53,"targetDuration":4,"studyType":23,"phases":55,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":61,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":45},"100524093","phase-2-129-xenon-mri-as-a-biomarker-for-diagnosis-and-response-to-therapy-in-pulmonary-arterial-hypertension-pah-100524093","NCT06104228","129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH)","Xenon PAH Bio","Inclusion Criteria:\n\nArm 1 -IPAH\n\n* Age: 18-75 years\n* WHO functional class 2 or 3\n* Mean pulmonary artery pressures \\> 20 mmHg\n* Pulmonary capillary wedge pressure ≤15 mmHg\n* Pulmonary vascular resistance \\> 2 Wood Units (WU)\n* No other cause identified for PAH\n\nArm 2 -PAH-CTD\n\n* Age: 18-75 years\n* WHO functional class (FC) 2 or 3\n* Mean pulmonary artery pressures \\> 20 mmHg\n* Pulmonary capillary wedge pressure ≤15 mmHg\n* Pulmonary vascular resistance \\> 2 WU\n* Diagnosis of connective tissue disease\n\nExclusion Criteria:\n\n* PH other than Idiopathic PAH or PAH associated with CTD; any conditions that prevent the performance of 129Xe MRI scans will be excluded from the study.",{"count":54,"type":22},20,[25],"The overall study objectives outlined in this study are to derive 129Xe MRI pulmonary vascular biomarker signatures that differentiate common subtypes of PAH and to determine the ability of 129Xe MRI to longitudinally monitor disease progression and response to therapy in PAH, with the aid of additional assessments, such as labs, echocardiography, and six-minute walk distance (6MWD).",[29,58,59,60],"Idiopathic Pulmonary Arterial Hypertension","Pulmonary Arterial Hypertension Associated With Connective Tissue Disease (Disorder)","Connective Tissue Diseases",{"date":36,"type":37},{"date":63,"type":37},"2024-08-12",{"date":65,"type":22},"2027-03-31",{"name":43,"class":44},{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":23,"phases":77,"briefSummary":78,"conditions":79,"keywords":82,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":85,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":45},"100422224","phase-2-pulmonary-hypertension-solar-100422224","NCT04778046","Pulmonary Hypertension SOLAR","Defining a Noninvasive Signature for Pulmonary Vascular Remodeling in Group 3 PH","PH SOLAR","Inclusion Criteria:\n\n1. Age ≥ 18 years' old\n2. Be on the lung transplant waiting list at Duke University Medical Center.\n3. PH as defined by RHC - mPAP \\> 20 mmHg, PVR \\> 3 WU, PCWP \\\u003C 15 mmHg\n4. Groups defined as:\n\n   PAH: Clinical diagnosis of PAH (Group 1 PH) in the absence of severe chronic lung disease, left heart disease, chronic thromboembolism, sarcoidosis, sickle cell disease, or other causes of non-Group 1 PH.\n\n   COPD-noPH: Clinical diagnosis of COPD in the absence of precapillary PH.\n\n   COPD-PH: Clinical diagnosis of COPD with precapillary PH.\n\n   IPF-noPH: Clinical diagnosis of IPF in the absence of precapillary PH.\n\n   IPF-PH: Clinical diagnosis of IPF with precapillary PH.\n5. Willing and able to give informed consent and adhere to visit\u002Fprotocol schedules (consent must be given before any study procedures are performed).\n\nExclusion Criteria:\n\n1. Moderate to severe heart disease (LVEF \\\u003C 45% or severe LV Hypertrophy).\n2. Sarcoidosis.\n3. Active cancer.\n4. Sickle cell anemia.\n5. Liver disease (Childs-Pugh class C).\n6. Prisoners and pregnant women will not be approached for the study.\n7. Inability to obtain consent.\n8. Conditions that will prohibit MRI scanning (metal in eye, claustrophobia, inability to lie supine).\n9. Medical or psychological conditions which, in the opinion of the investigator, might create undue risk to the subject or interfere with the subject's ability to comply with the protocol requirements",{"count":76,"type":22},30,[25],"The main goal of this study is to develop a noninvasive signature for pulmonary vascular remodeling in Group 3 PH patients, using hyperpolarized 129Xe magnetic resonance imaging (129Xe MRI). Such a signature may identify Group 3 PH responders to PAH-specific therapies. PAH's unique 129Xe MRI signature has been shown in previous studies. Past studies have lacked a pathologic \"ground truth\" correlate of these signatures, which could be provided by comparing them with the pathology of lung explant tissue from patients who have undergone a lung transplant. This signature could be validated in a cohort of patients with Group 3 PH in future studies.",[80,81,29],"Interstitial Lung Disease","COPD",[83,84],"Lung Transplant","Group 3 PH",{"date":36,"type":37},{"date":87,"type":37},"2023-11-08",{"date":89,"type":22},"2028-07-31",{"name":43,"class":44},{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":4,"eligibilityCriteria":97,"healthyVolunteers":98,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":99,"targetDuration":4,"studyType":23,"phases":101,"briefSummary":102,"conditions":103,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":45},"100519060","phase-2-129xe-mri-cardiopulmonary-100519060","NCT06038630","129Xe MRI Cardiopulmonary","129Xe Gas Exchange MRI to Visualize Cardiopulmonary Function","Inclusion Criteria for Healthy Volunteers:\n\n(Inclusion Criteria: Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the trial)\n\n1. Outpatients of either gender, age \\> 18\n2. Willing and able to give informed consent and adhere to visit\u002Fprotocol (Consent must be given before any study procedures are performed.)\n3. Subject has no diagnosed pulmonary conditions\n4. Subject has not smoked in the previous 5 years\n5. Smoking history, if any, is less than or equal to 5 pack-years\n6. No history of using other inhaled products more than 1\u002Fweek for \\> 1 year\n\nInclusion Criteria for Transfusion and Phlebotomy Patients:\n\n1. In-patient or outpatients of either sex, age \\> 18\n2. Willing and able to give informed consent and adhere to visit\u002Fprotocol\n\nAnd one of the following:\n\n1. Patients who are scheduled to receive a red cell transfusion for anemia.\n2. Patients who are scheduled to undergo therapeutic phlebotomy to treat erythrocytosis or polycythemia\n3. Healthy volunteers undergoing voluntary whole blood donation (healthy volunteer inclusion criteria noted above)\n\nInclusion Criteria for Oxygen Administration Patients:\n\n1. In-patient or outpatients of either sex, age \\> 18\n2. Willing and able to give informed consent and adhere to visit\u002Fprotocol\n\nAnd one of the following categories (ILD, Dyspnea, CTEPH, or Healthy):\n\n1. Interstitial Lung Disease or Dyspnea\n\n   * Physician diagnosis of Interstitial Lung Disease by a pulmonologist using established criteria or physician referral of patient with dyspnea\n\n   OR\n2. Chronic Thromboembolic Pulmonary Hypertension (CTEPH)\n\n   * Patients with a diagnosis of CTEPH, defined as mean PA pressure \\>20 mmHg with a pulmonary vascular resistance \\>2 WU and pulmonary capillary wedge pressure ≤15 mmHg at right heart catheterization with evidence of chronic thromboembolic disease on clinical imaging after 3 months of anticoagulation\n   * Scheduled for pulmonary thromboendoarterectomy (PTE) surgery and willing to re-turn 3-6 months after for optional follow-up scans\n\n   OR\n3. Healthy Volunteer (criteria noted above)\n\nInclusion Criteria for Acute or Chronic Pulmonary Embolism Patients:\n\n1. In-patient or outpatients of either sex, age \\> 18\n2. Willing and able to give informed consent and adhere to visit\u002Fprotocol\n\nAnd one of the following categories (Acute or Chronic)\n\n1. Acute Pulmonary Embolism\n\n   * Patients presenting with acute PE 24-48hrs post-admission\n   * Willing to return after 3-6 months of anti-coagulation therapy\n\n   OR\n2. Chronic Thromboembolic Pulmonary Hypertension (CTEPH)\n\n   * Patients with a diagnosis of CTEPH, defined as mean PA pressure \\>20 mmHg with a pulmonary vascular resistance \\>2 WU and pulmonary capillary wedge pressure ≤15 mmHg at right heart catheterization with evidence of chronic thromboembolic disease on clinical imaging after 3 months of anticoagulation\n   * Scheduled for pulmonary thromboendoarterectomy (PTE) surgery and willing to re-turn 3-6 months after for optional follow-up scans\n\nExclusion Criteria for All subjects:\n\nSubjects presenting with any of the following will not be included in the trial:\n\n1. MRI is contraindicated based on responses to MRI screening questionnaire\n2. Subject is pregnant or lactating\n3. Resting O2 saturation \\\u003C90% with maximum supplemental O2 delivered by nasal canula\n4. Respiratory illness of a bacterial or viral etiology within 30 days of MRI\n5. Subject has history of any known ventricular cardiac arrhythmia\n6. Subject has history of cardiac arrest within the last year\n7. Subject does not fit into 129Xe vest coil used for MRI\n8. Subject cannot hold his\u002Fher breath for 10 seconds\n9. Subject deemed unlikely to be able to comply with instructions during imaging\n10. Medical or psychological conditions which, in the opinion of the investigator, might create undue risk to the subject or interfere with the subject's ability to comply with the protocol requirements",true,{"count":100,"type":22},125,[25],"The goal of this NIH-sponsored study is to characterize three biomarkers derived from 129Xe gas exchange MRI and to understand how they change in response to interventions.",[80,104,105,106,107,108],"Chronic Thromboembolic Pulmonary Hypertension","Acute Pulmonary Embolism","Anemia","Polycythemia","Dyspnea","2026-02-02",{"date":111,"type":37},"2026-02-04",{"date":113,"type":37},"2024-01-12",{"date":115,"type":22},"2028-06-30",{"name":43,"class":44},{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":4,"eligibilityCriteria":123,"healthyVolunteers":98,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":124,"targetDuration":4,"studyType":23,"phases":126,"briefSummary":127,"conditions":128,"keywords":129,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":45},"100154344","phase-2-hyperpolarized-129xe-mri-for-imaging-pulmonary-function-100154344","NCT01280994","Hyperpolarized 129Xe MRI for Imaging Pulmonary Function","Hyperpolarized 129Xe MR Imaging of the Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease","Inclusion Criteria:\n\nInclusion Criteria for Healthy Control Subjects\n\n1. Subject has no diagnosed pulmonary conditions\n2. Subject has not smoked in the previous 5 years.\n3. Smoking history, if any, is less than or equal to 5 pack-years.\n\nInclusion Criteria for Subjects with lung disease\n\n1. Subject has a diagnosis of pulmonary dysfunction made by a physician\n2. No acute worsening of pulmonary function in the past 30 days\n\nExclusion Criteria:\n\n1. Subject is less than 18 years old\n2. MRI is contraindicated based on responses to MRI screening questionaire\n3. Subject is pregnant or lactating\n4. Respiratory illness of a bacterial or viral etiology within 30 days of MRI\n5. Subject has received an investigational medicinal product (not including 129Xe) within 30 days of MRI\n6. Subject has any form of known cardiac arrhythmia\n7. Subject does not fit into 129Xe vest coil used for MRI\n8. Subject cannot hold his\u002Fher breath for 15 seconds\n9. Subject deemed unlikely to be able to comply with instructions during imaging",{"count":125,"type":22},445,[25],"The purpose of this study is to develop and evaluate the usefulness of MRI using 129Xe gas for regional assessment of pulmonary function. Specifically, three forms of 129Xe MRI contrast will be the investigators focus - 1) imaging of the 129Xe ventilation distribution, 2) imaging the alveolar microstructure via the 129Xe apparent diffusion coefficient (ADC), and 3) imaging 129Xe that dissolves in the pulmonary blood and tissues upon inhalation. Such imaging of 129Xe gas transfer is expected to be uniquely sensitive to pathologies affecting gas exchange (fibrosis, emphysema, pulmonary hypertension) and provide new insights regarding the normal resting heterogeneity of pulmonary gas exchange.",[80],[130,131,132,32],"Lung Disease","Pulmonary Disease","Diagnostic Imaging","2026-01-14",{"date":135,"type":37},"2026-01-16",{"date":137,"type":4},"2011-01",{"date":139,"type":22},"2030-12",{"name":43,"class":44},{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":4,"eligibilityCriteria":147,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":148,"enrollmentInfo":149,"targetDuration":4,"studyType":151,"phases":4,"briefSummary":152,"conditions":153,"keywords":155,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":163,"leadSponsor":165,"locationsCount":45},"100603698","downstream-effects-of-airway-mucus-plugs-on-129xenon-mri-in-severe-asthma-100603698","NCT07139899","Downstream Effects of Airway Mucus Plugs on 129Xenon MRI in Severe Asthma","Downstream Effects of Airway Mucus Plugs on 129Xenon MRI Following Biologic Therapy","Inclusion Criteria:\n\n* Adequate completion of informed consent process with written documentation\n* Patients 18 - 65 years old\n* Physician diagnosis of asthma for \\> 1 year\n* Able to perform reproducible spirometry according to ATS criteria based on clinical PFTs within previous 30 days of enrollment\n* All racial\u002Fethnic backgrounds may participate\n* Blood eosinophil count \\> 300 cells\u002FμL\n* Smoking history \\\u003C10 pack years\n* No smoking history (including vapes, cigar, or marijuana use) in the last 3 months\n* About to initiate asthma therapy with either dupilumab, tezepelumab, or benralizumab as part of their standard of care\n\nExclusion Criteria:\n\n* Respiratory tract infection within the 4 weeks prior to Visit 1\n* Body mass index (BMI) \\> 30 at Visit 1\n* One-time doses such as intra-articular injections require a 4-week washout prior to Visit 1\n* Asthma-related ER visit within the previous 4 weeks of Visit 1 or at any time while on the study\n* Significant concomitant medical illness, including (but not limited to) heart disease, cancer, uncontrolled diabetes, other chronic lung diseases (determined by the Investigator.)\n* Resting O2 saturation \\\u003C90% with maximum supplemental O2 delivered by nasal cannula\n* Positive urine pregnancy test at Visit 1 or at any time while on the study\n* Participation in an intervention study (including bronchoscopy) or use of investigative drugs within the past 30 days or plans to enroll in such a trial during the study\n* Unable or unlikely to complete study assessments in the opinion of the Investigator\n* Study intervention poses undue risk to patient in the opinion of the Investigator\n* Conditions that will prohibit MRI scanning determined by the MRI safety screening.","65 Years",{"count":150,"type":22},5,"OBSERVATIONAL","In this study, xenon MRI will be used to evaluate regional functional consequences of mucus plugs in the lungs of patients with severe asthma. Mucus plugs will be identified using CT imaging, and xenon MRI will be used to evaluate ventilation and gas exchange impairments in regions of the lungs corresponding to the airways downstream of mucus plugs.",[154],"Severe Asthma",[156,157,158],"xenon","asthma","mucus","2025-11-17",{"date":161,"type":37},"2025-11-20",{"date":159,"type":37},{"date":164,"type":22},"2027-09",{"name":43,"class":44},{"id":167,"slug":168,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":170,"acronym":171,"eligibilityCriteria":172,"healthyVolunteers":11,"sex":17,"minAge":173,"maxAge":4,"enrollmentInfo":174,"targetDuration":4,"studyType":23,"phases":176,"briefSummary":177,"conditions":178,"keywords":181,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":45},"100595852","phase-2-inhaled-treprostinil-tyvaso-nebulizer-for-copd-patients-with-hypoxemia-100595852","NCT07037836","Inhaled Treprostinil (Tyvaso Nebulizer) For COPD Patients With Hypoxemia","Tyvaso","Inclusion Criteria\n\n* Outpatients of either gender, age ≥ 40.\n* Clinical evidence of chronic bronchitis (a productive cough lasting more than 3 months within a 2-year period).\n* Current or former cigarette smokers with a smoking history of 20 or more pack-years.\n* Clinical diagnosis of chronic obstructive pulmonary disease (COPD) confirmed by spirometry demonstrating forced expiratory volume in 1 second (FEV1) to forced vital capacity (FVC) ratio \\\u003C 0.70, pre-bronchodilator FEV1 ≥ 30% predicted, and diffusing capacity of the lungs for carbon monoxide (DLCO) ≥ 45% predicted.\n* On stable maintenance COPD medications including inhaled corticosteroids (ICS), long-acting beta agonists (LABA), long-acting muscarinic antagonists (LAMA), combination inhalers, azithromycin, or roflumilast (with no changes over the past 3 months).\n* Patients with hypoxemia, evidenced by the use of supplemental oxygen at rest or during exercise (≤ 4 liters\u002Fminute).\n* Willing and able to give informed consent and adhere to visit and protocol schedules (consent must be obtained prior to any study procedures).\n* Women of childbearing potential must have a negative serum pregnancy test, confirmed prior to participation in this investigational protocol.\n\nExclusion Criteria\n\n* Upper respiratory tract infection within 6 weeks (participants may be rescreened after this period).\n* History of lung resection surgery or pleural decortication.\n* Previous history of pneumothorax.\n* Imaging evidence of interstitial lung disease, occupational lung disease, or chronic infectious lung disease.\n* History of asthma.\n* History of exposure to occupational or environmental hazards known to cause lung disease.\n* Positive pregnancy test for women of childbearing potential.\n* Major chronic illness that, in the judgment of the study physician, would interfere with participation in the study.\n\nFor Magnetic Resonance Imaging (MRI):\n\n* Contraindications to MRI based on screening questionnaire responses.\n* Participant is pregnant or lactating.\n* Respiratory illness of bacterial or viral etiology within 6 weeks prior to MRI.\n* Known cardiac arrhythmia.\n* Participant does not fit into the hyperpolarized xenon-129 (\\^129Xe) vest coil used for MRI.\n* Participant cannot hold their breath for 10 seconds.\n* Participant is unlikely to comply with instructions during imaging.","40 Years",{"count":175,"type":22},10,[25],"The goal of this clinical trial is to evaluate whether inhaled Treprostinil (Tyvaso) can improve oxygen delivery and blood flow in the lungs in adults (age ≥40) with chronic obstructive pulmonary disease (COPD) and hypoxemia who have less severe reduction in lung blood volume (diffusing capacity of the lungs for carbon monoxide \\[DLCO\\] ≥45%).\n\nThe main questions it aims to answer are:\n\n1. Does inhaled Treprostinil increase pulmonary capillary blood volume in ventilated lung regions, as measured by hyperpolarized xenon-129 magnetic resonance imaging (HP129Xe MRI)?\n2. Does inhaled Treprostinil improve oxygen delivery (measured as red blood cell \\[RBC\\] chemical shift) and maintain or only slightly change pulmonary vascular resistance (measured by RBC oscillation amplitude)?\n3. Can pre-treatment MRI parameters (RBC transfer and RBC oscillation amplitude) predict who will respond to inhaled Treprostinil?\n\nParticipants will:\n\n* Use the Tyvaso nebulizer (inhaled Treprostinil) 4 times daily for 4 weeks, starting at 3 breaths per session and increasing to a maximum of 6 breaths per session as tolerated.\n* Undergo HP129Xe MRI before and after treatment to assess regional lung function and oxygen exchange.\n* Complete pulmonary function tests (PFTs), 6-minute walk tests (6MWT), and echocardiograms at the beginning and end of the study.\n* Be monitored for adverse events, with a phone check-in midway through and after the treatment period.",[179,180],"COPD (Chronic Obstructive Pulmonary Disease)","Hypoxemia",[171,81,180],"2025-10-29",{"date":184,"type":37},"2025-10-30",{"date":186,"type":37},"2025-09-29",{"date":188,"type":22},"2027-07-01",{"name":43,"class":44},""]